BRPI0920304A2 - compound, pharmaceutical composition and respective uses and method of inhibiting ns3 / ns4 protease activity in vitro. - Google Patents

compound, pharmaceutical composition and respective uses and method of inhibiting ns3 / ns4 protease activity in vitro.

Info

Publication number: BRPI0920304A2
Authority: BR; Brazil
Prior art keywords: vitro; inhibiting; compound; pharmaceutical composition; protease activity
Prior art date: 2008-10-15

Application number

BRPI0920304A

Other languages

Portuguese (pt)

Inventor

Dimitrova Stoycheva Antitsa

A Bucher Brad

Beigelman Leonid

Seiwert Scott

Serebryany Vladimir

Original Assignee

Intermune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-15

Filing date

2009-10-13

Publication date

2019-09-24

2009-10-13 Application filed by Intermune Inc filed Critical Intermune Inc

2009-10-13 Priority claimed from PCT/US2009/060558 external-priority patent/WO2010045266A1/en

2019-09-24 Publication of BRPI0920304A2 publication Critical patent/BRPI0920304A2/en

Links

108091005804 Peptidases Proteins 0.000 title 1
239000004365 Protease Substances 0.000 title 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000000694 effects Effects 0.000 title 1
238000000338 in vitro Methods 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

BRPI0920304A 2008-10-15 2009-10-13 compound, pharmaceutical composition and respective uses and method of inhibiting ns3 / ns4 protease activity in vitro. BRPI0920304A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10574608P	2008-10-15	2008-10-15
PCT/US2009/060558 WO2010045266A1 (en)	2008-10-15	2009-10-13	Therapeutic antiviral peptides

Publications (1)

Publication Number	Publication Date
BRPI0920304A2 true BRPI0920304A2 (en)	2019-09-24

Family

ID=68066502

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0920304A BRPI0920304A2 (en)	2008-10-15	2009-10-13	compound, pharmaceutical composition and respective uses and method of inhibiting ns3 / ns4 protease activity in vitro.

Country Status (1)

Country	Link
BR (1)	BRPI0920304A2 (en)

2009
- 2009-10-13 BR BRPI0920304A patent/BRPI0920304A2/en not_active IP Right Cessation

Similar Documents

Publication	Publication Date	Title
BRPI0911260A2 (en)	2015-09-29	compound, pharmaceutical composition, method of inhibiting ns3 / ns4 protease activity in vitro, and uses of compounds
BRPI0911259A2 (en)	2015-10-06	compound, pharmaceutical composition, method of inhibiting ns5b polymerase activity in vitro and uses of compounds
BRPI0908021A2 (en)	2015-07-21	Compound, Pharmaceutical Composition, and, Uses of Compound or Pharmaceutical Composition
IT1392423B1 (en)	2012-03-02	STRUCTURE OF GLOVE, IN PARTICULAR OF MOTORCYCLING, AND METHOD FOR ITS REALIZATION.
BRPI0910503A2 (en)	2015-09-29	compounds, pharmaceutical compositions and their uses.
DK2395984T4 (en)	2026-02-23	PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN AND AN SGLT2 INHIBITOR, AND USES THEREOF
BRPI0909030A2 (en)	2018-03-13	modified release pharmaceutical compositions comprising mycophenolate and processes therefor.
BRPI1009372A2 (en)	2016-05-31	compounds, pharmaceutical composition and their uses
BRPI0918360A2 (en)	2017-10-10	compound, pharmaceutical composition and uses of a compound
BRPI0914343A2 (en)	2016-07-26	composition, product, use of composition and method
BRPI1010772A2 (en)	2016-11-01	compound and pharmaceutical composition.
BRPI0811447A2 (en)	2014-10-29	COMPOUNDS, PHARMACEUTICAL COMPOSITION, AND METHODS OF INHIBITING NS3 / NS4 PROTEASE ACTIVITY, HEPATIC FIBROSIS TREATMENT AND HEPATIC FUNCTION INTENSIFICATION IN AN INDIVIDUAL HAVING HEPATITIS C VIRUS INFECTION.
BRPI0906962A2 (en)	2015-07-14	Compound and pharmaceutical composition
BRPI0906556A2 (en)	2015-07-07	Compound and pharmaceutical composition
PT1849470T (en)	2017-09-22	ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHA-TRIFLUOROTIMIDIN AND TIMIDINE-PHOSPHORYLASE INHIBITOR
BRPI1014583A2 (en)	2016-04-26	heterocyclic sulfonamides, pharmaceutical compositions and uses thereof.
EP2252670A4 (en)	2015-06-10	AZETROPENIC COMPOSITION OF 1,1,1-TRIFLUORO-3-CHLOROPROPENE AND TRANS-1,2-DICHLOROETHYLENE
BRPI0918652A2 (en)	2015-08-25	Pharmaceutical compositions and related release methods.
DK3599279T3 (en)	2026-03-30	COMPOSITIONS AND METHODS INCLUDING PROTEASE VARIANTS
PT1902706T (en)	2017-02-08	Stable pharmaceutical compositions of tetracyclines in solution, method for obtaining them and their uses
BRPI0905369A2 (en)	2015-06-30	Pharmaceutical composition, composition and compartmentalized kit
BRPI0822337A2 (en)	2015-06-16	Folates, compositions and uses thereof
SMP201000003B (en)	2010-11-12	Composition, method and preparation of synthetic bile acids.
BRPI0917681A2 (en)	2015-08-04	Compound and pharmaceutical composition
EP2429987A4 (en)	2012-10-03	AMID COMPOUND, PHARMACEUTICAL METHOD AND PHARMACEUTICAL COMPOSITION THEREFOR

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application fees: dismissal - article 86 of industrial property law
2020-01-21	B08K	Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.